419 studies found for:    PAH
Show Display Options
Rank Status Study
21 Not yet recruiting Carbon Monoxide Therapy for Severe Pulmonary Arterial Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: Carbon Monoxide
22 Completed AC-055-402: An Extension of AC-055-401, Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Macitentan
23 Unknown  Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
24 Completed
Has Results
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: ACT-385781A (Actelion Epoprostenol);   Drug: Flolan®
25 Recruiting Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab;   Other: Placebo
26 Active, not recruiting DelIVery for Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Device: The Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System to deliver Remodulin Injection
27 Completed PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PSA-Activated PSA-PAH1
28 Terminated A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: AIR001 (sodium nitrite inhalation solution)
29 Active, not recruiting Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
Condition: Pulmonary Arterial Hypertension
Interventions: Drug: inhaled prostacyclin;   Drug: prostacyclin;   Drug: subcutaneous and intravenous prostacyclin;   Drug: oral ERA;   Drug: oral PDE5 inhibitors
30 Completed
Has Results
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: sildenafil citrate
31 Recruiting Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
Condition: Pre-Pulmonary Atrial Hypertension
Intervention: Drug: Ambrisentan
32 Completed Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Sorafenib
33 Active, not recruiting Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: BPS-314d-MR
34 Recruiting Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Conditions: Muscle Weakness;   Pulmonary Arterial Hypertension
Intervention:
35 Completed
Has Results
FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) Sustained Release Tablets;   Other: Placebo
36 Terminated
Has Results
Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety
Conditions: Pulmonary Arterial Hypertension;   Pulmonary Hypertension
Interventions: Drug: Sitaxsentan;   Drug: Sitaxsentan and Sildenafil
37 Recruiting National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention:
38 Completed
Has Results
FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)
Condition: Pulmonary Hypertension
Interventions: Drug: Oral treprostinil (UT-15C) sustained release tablets;   Drug: Placebo
39 Recruiting The Expression and Significance of MiRNA
Condition: Pulmonary Arterial Hypertension
Intervention:
40 Recruiting Drug Therapy and Surgery in Congenital Heart Disease With Pulmonary Hypertension
Conditions: Congenital Heart Disease;   Pulmonary Arterial Hypertension
Intervention: Drug: Sildenafil singly or in association with Bosentan

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years